Big Pharma's "pay-for-delay" deals block cheaper generics, costing $50B+ over 10 years.

The claim that 'Big Pharma's pay-for-delay deals block cheaper generics, costing $50B+ over 10 years' involves several components: first, that branded drug manufacturers pay generic competitors to delay market entry; second, that this practice effectively blocks cheaper generics; and third, that the financial impact exceeds $50 billion over a decade. Evidence from multiple sources confirms that pay-for-delay agreements are a documented anticompetitive practice where brand-name drug companies compensate generic manufacturers to postpone launching lower-cost alternatives.captimes.comcaptimes.comBruce Speight: Using 'pay for delay,' Big Pharma pockets $98 billion

This delay maintains higher prices for branded drugs, harming consumers and healthcare payers by preventing access to more affordable generics.pirg.orgpirg.orgBig Pharma's Pay-for-Delay Deals Take a Hit Legal scrutiny and regulatory actions have targeted these deals as harmful to competition.pirg.orgpirg.orgTop Twenty Pay-For-Delay Drugs Regarding the financial cost, estimates vary but several analyses place the cumulative cost burden on consumers and health systems in the tens of billions over periods roughly spanning a decade or more.

For example, one source cites $98 billion in related profits from pay-for-delay practices,captimes.comcaptimes.comBruce Speight: Using 'pay for delay,' Big Pharma pockets $98 billion which aligns with the claim's scale. While exact figures depend on methodology and scope, the $50 billion+ figure is consistent with credible estimates. Some nuance exists as not all pay-for-delay deals are identical in impact or legality, and ongoing reforms aim to reduce their prevalence.drugwatch.comdrugwatch.comBig Pharma’s Block on Competition a Bad Prescription for U.S. Drug Prices

Overall, the claim accurately reflects the core facts about pay-for-delay deals and their substantial economic consequences.